Cargando…

The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients

A method of rapidly pointing out the risk of developing persistent pulmonary fibrosis from a sample of blood is extraordinarily needed for diagnosis, prediction of death, and post-infection prognosis assessment. Collagen scar formation has been found to play an important role in the lung remodeling...

Descripción completa

Detalles Bibliográficos
Autores principales: Wybranowski, Tomasz, Pyskir, Jerzy, Bosek, Maciej, Napiórkowska, Marta, Cyrankiewicz, Michał, Ziomkowska, Blanka, Pilaczyńska-Cemel, Marta, Pyskir, Małgorzata, Rogańska, Milena, Kruszewski, Stefan, Przybylski, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457233/
https://www.ncbi.nlm.nih.gov/pubmed/36079011
http://dx.doi.org/10.3390/jcm11175081
_version_ 1784786005451079680
author Wybranowski, Tomasz
Pyskir, Jerzy
Bosek, Maciej
Napiórkowska, Marta
Cyrankiewicz, Michał
Ziomkowska, Blanka
Pilaczyńska-Cemel, Marta
Pyskir, Małgorzata
Rogańska, Milena
Kruszewski, Stefan
Przybylski, Grzegorz
author_facet Wybranowski, Tomasz
Pyskir, Jerzy
Bosek, Maciej
Napiórkowska, Marta
Cyrankiewicz, Michał
Ziomkowska, Blanka
Pilaczyńska-Cemel, Marta
Pyskir, Małgorzata
Rogańska, Milena
Kruszewski, Stefan
Przybylski, Grzegorz
author_sort Wybranowski, Tomasz
collection PubMed
description A method of rapidly pointing out the risk of developing persistent pulmonary fibrosis from a sample of blood is extraordinarily needed for diagnosis, prediction of death, and post-infection prognosis assessment. Collagen scar formation has been found to play an important role in the lung remodeling following SARS-CoV-2 infection. For this reason, the concentration of collagen degradation products in plasma may reflect the process of lung remodeling and determine the extent of fibrosis. According to our previously published results of an in vitro study, an increase in the concentration of type III collagen degradation products in plasma resulted in a decrease in the fluorescence lifetime of plasma at a wavelength of 450 nm. The aim of this study was to use time-resolved fluorescence spectroscopy to assess pulmonary fibrosis, and to find out if the lifetime of plasma fluorescence is shortened in patients with COVID-19. The presented study is thus far the only one to explore the fluorescence lifetime of plasma in patients with COVID-19 and pulmonary fibrosis. The time-resolved spectrometer Life Spec II with the sub-nanosecond pulsed 360 nm EPLED® diode was used in order to measure the fluorescence lifetime of plasma. The survival analysis showed that COVID-19 mortality was associated with a decreased mean fluorescence lifetime of plasma. The AUC of mean fluorescence lifetime in predicting death was 0.853 (95% CI 0.735–0.972, p < 0.001) with a cut-off value of 7 ns, and with 62% sensitivity and 100% specificity. We observed a significant decrease in the mean fluorescence lifetime in COVID-19 non-survivors (p < 0.001), in bacterial pneumonia patients without COVID-19 (p < 0.001), and in patients diagnosed with idiopathic pulmonary fibrosis (p < 0.001), relative to healthy subjects. Furthermore, these results suggest that the development of pulmonary fibrosis may be a real and serious problem in former COVID-19 patients in the future. A reduction in the mean fluorescence lifetime of plasma was observed in many patients 6 months after discharge. On the basis of these data, it can be concluded that a decrease in the mean fluorescence lifetime of plasma at 450 nm may be a risk factor for mortality, and probably also for pulmonary fibrosis in hospitalized COVID-19 patients.
format Online
Article
Text
id pubmed-9457233
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94572332022-09-09 The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients Wybranowski, Tomasz Pyskir, Jerzy Bosek, Maciej Napiórkowska, Marta Cyrankiewicz, Michał Ziomkowska, Blanka Pilaczyńska-Cemel, Marta Pyskir, Małgorzata Rogańska, Milena Kruszewski, Stefan Przybylski, Grzegorz J Clin Med Article A method of rapidly pointing out the risk of developing persistent pulmonary fibrosis from a sample of blood is extraordinarily needed for diagnosis, prediction of death, and post-infection prognosis assessment. Collagen scar formation has been found to play an important role in the lung remodeling following SARS-CoV-2 infection. For this reason, the concentration of collagen degradation products in plasma may reflect the process of lung remodeling and determine the extent of fibrosis. According to our previously published results of an in vitro study, an increase in the concentration of type III collagen degradation products in plasma resulted in a decrease in the fluorescence lifetime of plasma at a wavelength of 450 nm. The aim of this study was to use time-resolved fluorescence spectroscopy to assess pulmonary fibrosis, and to find out if the lifetime of plasma fluorescence is shortened in patients with COVID-19. The presented study is thus far the only one to explore the fluorescence lifetime of plasma in patients with COVID-19 and pulmonary fibrosis. The time-resolved spectrometer Life Spec II with the sub-nanosecond pulsed 360 nm EPLED® diode was used in order to measure the fluorescence lifetime of plasma. The survival analysis showed that COVID-19 mortality was associated with a decreased mean fluorescence lifetime of plasma. The AUC of mean fluorescence lifetime in predicting death was 0.853 (95% CI 0.735–0.972, p < 0.001) with a cut-off value of 7 ns, and with 62% sensitivity and 100% specificity. We observed a significant decrease in the mean fluorescence lifetime in COVID-19 non-survivors (p < 0.001), in bacterial pneumonia patients without COVID-19 (p < 0.001), and in patients diagnosed with idiopathic pulmonary fibrosis (p < 0.001), relative to healthy subjects. Furthermore, these results suggest that the development of pulmonary fibrosis may be a real and serious problem in former COVID-19 patients in the future. A reduction in the mean fluorescence lifetime of plasma was observed in many patients 6 months after discharge. On the basis of these data, it can be concluded that a decrease in the mean fluorescence lifetime of plasma at 450 nm may be a risk factor for mortality, and probably also for pulmonary fibrosis in hospitalized COVID-19 patients. MDPI 2022-08-30 /pmc/articles/PMC9457233/ /pubmed/36079011 http://dx.doi.org/10.3390/jcm11175081 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wybranowski, Tomasz
Pyskir, Jerzy
Bosek, Maciej
Napiórkowska, Marta
Cyrankiewicz, Michał
Ziomkowska, Blanka
Pilaczyńska-Cemel, Marta
Pyskir, Małgorzata
Rogańska, Milena
Kruszewski, Stefan
Przybylski, Grzegorz
The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
title The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
title_full The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
title_fullStr The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
title_full_unstemmed The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
title_short The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
title_sort mortality risk and pulmonary fibrosis investigated by time-resolved fluorescence spectroscopy from plasma in covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457233/
https://www.ncbi.nlm.nih.gov/pubmed/36079011
http://dx.doi.org/10.3390/jcm11175081
work_keys_str_mv AT wybranowskitomasz themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT pyskirjerzy themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT bosekmaciej themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT napiorkowskamarta themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT cyrankiewiczmichał themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT ziomkowskablanka themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT pilaczynskacemelmarta themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT pyskirmałgorzata themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT roganskamilena themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT kruszewskistefan themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT przybylskigrzegorz themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT wybranowskitomasz mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT pyskirjerzy mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT bosekmaciej mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT napiorkowskamarta mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT cyrankiewiczmichał mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT ziomkowskablanka mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT pilaczynskacemelmarta mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT pyskirmałgorzata mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT roganskamilena mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT kruszewskistefan mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients
AT przybylskigrzegorz mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients